Cresco Labs (CRLBF) Common Equity (2019 - 2026)

Cresco Labs' Common Equity history runs 8 years deep, the most recent figure standing at $244.2 million for Q1 2026.

• Quarterly Common Equity fell 34.98% year-over-year to $244.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $244.2 million (down 34.98% YoY) and the FY2025 annual result came in at $252.5 million, down 34.95% from the prior year.
• Common Equity was $244.2 million for Q1 2026 at Cresco Labs, down from $252.5 million in the prior quarter.
• Across five years, Common Equity topped out at $783.6 million in Q2 2022 and bottomed at $244.2 million in Q1 2026.
• A 5-year average of $470.4 million and a median of $420.0 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity rose 8.31% — and 2023, when it sank 44.8%.
• Cresco Labs' Common Equity stood at $587.7 million in 2022, then retreated by 27.16% to $428.1 million in 2023, then slipped by 9.32% to $388.2 million in 2024, then slumped by 34.95% to $252.5 million in 2025, then slipped by 3.28% to $244.2 million in 2026.
• Business Quant data shows CRLBF's Common Equity at $244.2 million in Q1 2026, $252.5 million in Q4 2025, and $340.2 million in Q3 2025.